A highly potent and uniquely specific tyrosine kinase inhibitor of a rationally engineered v-Src tyrosine kinase
A cell-permeable C3-enlarged PP1 (Cat. No. 567809) analog that is shown to act as a potent, ATP-competitive, and highly ASKA- (analog-sensitive kinase alleles) selective inhibitor against polo-like kinase 1C67V L130G (75% and 94% inhibition in cell-free kinase assays at 0.1 and 1 μM, respectively), ZAP-70C405V M414A/ZAP-70M414A (complete prevention and elimination, respectively, of αTCR-stimulated [Ca2+] elevation in ASKA transfectants when applied before or after αTCR stimulation at 6 μM), and SykM442A S505A (56% inhibition of phagocytosis of Ab-opsonized SRBC by ASKA macrophages at 6 μM), while exhibiting little or no activity toward the wild-type or other off-target cellular enzymes. Functional analog-sensitive allele mutants are valuable tools in pharmacological validation of drug development and in elucidating enzyme signalings and functions both in cultures in vitro and in animals in vivo when specific inhibitors against naturally occurring target enzymes are unavailable and/or generations of knockout animals/cells lacking the target enzymes appear to be difficult, infeasible, or simply impossible.
3mb-pp1 is a cell-permeable, potent, atp-competitive, and highly selective inhibitor of polo-like kinase.human polo-like kinase 1 (plk1) plays dominant role in mitosis and the maintenance of genomic stability. plk1 is overexpressed in human tumours and exihibits prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic target [2].
3mb-pp1 treatment significantly changed the dna state. in tbplkas cells, after treatment with 3mb-pp1 for 9 h, cells at all cell cycle stages showed an increase in detached new flagella when compared with vehicle control-treated samples [1]. the ic50 value of 3mb-pp1 against ptoas kinase activity was 120 nm. 3mb-pp1 was not able to significantly inhibit pti1 and mpk2. 3mb-pp1 significantly potentiated the interactions of ptoas with avrpto and avrptob1–387[3].
[1] lozano-núez a, ikeda k n, sauer t, et al. an analogue-sensitive approach identifies basal body rotation and flagellum attachment zone elongation as key functions of plk in trypanosoma brucei[j]. molecular biology of the cell, 2013, 24(9): 1321-1333.
[2] strebhardt k, ullrich a. targeting polo-like kinase 1 for cancer therapy[j]. nature reviews cancer, 2006, 6(4): 321-330.
[3] salomon d, bonshtien a, mayrose m, et al. bypassing kinase activity of the tomato pto resistance protein with small molecule ligands[j]. journal of biological chemistry, 2009, 284(22): 15289-15298.